Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Auto-Injectable Methotrexate: New Treatment Option for RA

Susan Bernstein  |  October 14, 2015

Methotrexate has long been a cornerstone of therapy in rheumatoid arthritis. Two new, injectable methotrexate products may help some RA patients for whom oral methotrexate is not as effective or causes adverse effects. Rasuvo and Otrexup are prefilled, auto-injection devices that allow patients to give themselves subcutaneous injections of methotrexate without having to use a…

Filed under:ConditionsRheumatoid Arthritis Tagged with:auto-injectable methotrexateClinicalDiagnosisMethotrexatepatient careRARheumatoid arthritisrheumatologistTreatment

Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA

Michele B. Kaufman, PharmD, BCGP  |  October 14, 2015

In a global Phase 3 trial, subcutaneous secukinumab proved safe and effective in patients with psoriatic arthritis. Also, a version of aspartyl-alanyl diketopiperazine, a biologic for knee OA, has entered Phase 3 trials…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone DisordersOther Rheumatic Conditions Tagged with:analgesicKnee Osteoarthritis (OA)PainPsoriatic Arthritissecukinumab

Case Report: Interstitial Lung Disease with Positive ANCA Test

Sara Tedeschi, MD  |  October 13, 2015

“Worst of all is the pain in my calves,” she said. “It feels like burning deep inside.” So began my first encounter with a 69-year-old woman who was referred to rheumatology clinic for evaluation of two months of constitutional symptoms and a positive ANCA test, which had been ordered by her primary care doctor. Her…

Filed under:Conditions Tagged with:ANCA patient careClinicalDiagnosisILDInterstitial Lung Diseaseoutcome

Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

Alessandro Villa, DDS, PhD, MPH, & Sook Bin Woo, DMD, MMSc  |  October 13, 2015

Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

Filed under:Conditions Tagged with:ClinicalOsteonecrosispatient carerheumatologyrhuematologist

Rheumatoid Arthritis Patients Have More Severe ACS, Poorer Outcomes

Shannon Aymes  |  October 9, 2015

NEW YORK (Reuters Health)—Rheumatoid arthritis (RA) is associated with more-severe acute coronary syndrome and poorer outcomes, according to a new study. “We found that despite the well-researched increased risk of acute coronary events (ACS) in RA, that there was almost no existing data describing clinical characteristics and outcomes of RA- and non-RA patients with ACS,”…

Filed under:ConditionsRheumatoid Arthritis Tagged with:acute coronary syndromeCardiovascular diseaseMyocardial infarctionOutcomesRheumatoid Arthritis (RA)

Bone Loss Common in Suspected Spondyloarthritis

David Douglas  |  October 8, 2015

NEW YORK (Reuters Health)—More than 40% of patients with early inflammatory back pain suggestive of axial spondyloarthritis (SpA) show bone loss over the course of two years, according to French researchers. SpA is known to be associated with bone loss at the spine and the hip and an increased risk of vertebral fractures. To investigate…

Filed under:Axial SpondyloarthritisConditionsOsteoarthritis and Bone Disorders Tagged with:Anti-TNFaxial spondyloarthritis (SpA)Back painbone lossbone mineral density (BMD)Osteoporosis

Immunotherapy May Be Effective for Some Patients with Autoimmune Cerebellar Ataxia

Will Boggs, MD  |  October 7, 2015

NEW YORK (Reuters Health)—Immunotherapy appears to yield neurological improvements in some patients with autoimmune cerebellar ataxia, especially those with nonparaneoplastic disorders, researchers report. “I was surprised that so many patients responded to immunotherapy (steroids, intravenous immunoglobulin (IVIg), and plasma exchange) and remained ambulatory,” Dr. Andrew McKeon from Mayo Clinic in Rochester, Minn., told Reuters Health…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Autoimmune Cerebellar AtaxiaAutoimmune diseaseCorticosteroidsimmunoglobulinimmunotherapyNeurologyrituximab

Ustekinumab Can Be Used to Safely Treat Teens & More

Michele B. Kaufman, PharmD, BCGP  |  October 7, 2015

A recent study showed ustekinumab can be used to treat teens with moderate to severe psoriasis. Also, Phase 2 trials for an analgesic combination drug show it holds promise for reducing post-operative pain…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:AdolescentsanalgesicBiologics & BiosimilarsPainustekinumab

Weight-Bearing Exercise Eases Knee Osteoarthritis, Temporarily

Kathryn Doyle  |  October 5, 2015

(Reuters Health)—A program of weight-bearing exercise reduces pain and improves joint function, at least for two to six months, for people with osteoarthritis, according to a review of previous trials. “We had a systematic review for Cochrane from 2008 and 2009, but there were much less articles,” said Dr. Martin Van der Esch, who coauthored…

Filed under:ConditionsOsteoarthritis and Bone Disorders

Rituximab for RA Is Safe Long Term, Plus Oxycodone Update

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2015

Rituximab was evaluated and found safe as a long-term RA therapy. Also, FDA Advisory Committees voted on oxycodone therapies at a joint meeting.

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:analgesicFDAFood and Drug AdministrationOxycodoneRheumatoid Arthritis (RA)rituximab

  • « Previous Page
  • 1
  • …
  • 167
  • 168
  • 169
  • 170
  • 171
  • …
  • 243
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences